57 results on '"Lars Lannfelt"'
Search Results
2. P4‐704: BAN2401 SHOWS STRONGER BINDING TO SOLUBLE AGGREGATED AMYLOID‐BETA SPECIES THAN ADUCANUMAB
3. DT‐01‐07: TREATMENT OF EARLY AD SUBJECTS WITH BAN2401, AN ANTI‐Aβ PROTOFIBRIL MONOCLONAL ANTIBODY, SIGNIFICANTLY CLEARS AMYLOID PLAQUE AND REDUCES CLINICAL DECLINE
4. P4‐233: AGED ALZHEIMER'S DISEASE BRAINS EXHIBIT NUMEROUS Aβ BUT ONLY FEW TAU PRIONS
5. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
6. [P2–055]: PHARMACOLOGICAL CHARACTERIZATION OF BAN2401‐MEDIATED Aβ PROTOFIBRIL CLEARANCE BY MICROGLIA
7. [P4–533]: GENOTYPE‐DEPENDENT LONGITUDINAL TRAJECTORIES OF COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE
8. P1‐007: NEURON‐TO‐NEURON TRANSMISSION OF ALPHA‐SYNUCLEIN
9. P3‐404: CONSIDERATION FOR 'EARLY ALZHEIMER'S DISEASE (AD)' TRIALS WITH A SINGLE PRODROMAL AD AND MILD AD DEMENTIA POPULATION: ADNI DATA ANALYSIS AND INITIAL OBSERVATIONS FROM THE BAN2401‐G000‐201 TRIAL
10. P2‐110: ELEVATED CEREBROSPINAL FLUID LEVELS OF NEUROGRANIN IN ALZHEIMER'S DISEASE
11. P4‐181: INITIAL LEARNINGS FROM SCREENING STRATEGIES IN THE BAN 2401‐G000‐201 TRIAL: AN EARLY ALZHEIMER'S DISEASE STUDY
12. P2–404: Clearance of beta‐amyloid protofibrils/oligomers in the brain and CSF of TG‐APP ARCSWE mice following treatment with the protofibril‐selective antibody mAb158
13. P4–053: Alpha‐synuclein oligomers can act as seed in a fibrillation assay but do not cause increased aggregation in living cells
14. P4–281: Microglial involvement and amyloid reduction with BAN2401/mAb158, a monoclonal antibody with high selectivity for protofibrils: In vitro and ex vivo analyses
15. P4–282: A multimodal imaging study of mAb158, a murine monoclonal antibody with high selectivity for amyloid protofibrils, in Tg2576 mice
16. O4–05–01: A first‐in‐human study of BAN2401, a novel monoclonal antibody against beta‐amyloid protofibrils
17. P4–286: Pharmacology of BAN2401: A monoclonal antibody selective for beta‐amyloid protofibrils
18. P1–073: Assessment of Alzheimer's disease risk genes with CSF‐biomarker levels
19. P2‐266: Morphological and functional properties of aldehyde‐induced alpha‐synuclein oligomers
20. P1‐036: Seeding of cross linked alpha‐synuclein oligomers in vitro and in vivo
21. P1‐240: Item analysis of adas‐cog and cdr system cognitive measures in ad patients on stable treatment with anticholinesterases
22. P3‐416: Aβ stimulation leads to elevated levels of heparan sulfate proteoglycans in glial cells
23. IC‐P2‐134: FDG‐PET studies in early‐onset familial Alzheimer's disease
24. O3‐02–04: Increased levels of CSF Aβ oligomers in Alzheimer's disease: Combination of techniques allows indirect estimates
25. P2‐359: Comparison of CDRs in conformation dependent Aβ antibodies
26. O3‐01–01: Amyloid‐β protofibrils are linked to cognitive impairment in Alzheimer's disease transgenic mice
27. P2‐372: Development of oligomer‐specific alpha‐synuclein antibodies
28. P1‐377: Sensitive detection of biomarkers of protein folding disorders: Proximity ligation‐based detection of protein oligomers
29. P2‐075: FDG‐PET studies in early‐onset familial Alzheimer's disease
30. P2‐218: Characterization of early events in the alpha‐synuclein aggregation pathway
31. P4‐108: Serum cystatin C and the risk of Alzheimer's disease
32. P1‐097: The arctic Alzheimer mutation alters structure and composition of Aβ deposits
33. P2–106: Proximity ligation–based detection of biomarkers of protein folding disorders
34. P2–160: Csf Aβ and tau levels in Alzheimer's disease and mild cognitive impairment
35. P1–230: Serum antioxidants and fish fatty acids in 50–year old men are not related to risk of Alzheimer's disease. A 35–year follow up of the Uppsala Longitudinal Study on Adult Men (ULSAM)
36. P3–302: Aggregational properties of wild–type and mutated tau protein
37. O1–06–05: Monoclonal antibodies selective for Aβ protofibrils reduce plaque burden in transgenic mice models of Alzheimer's disease
38. P4–026: The nature of monoclonal antibodies produced from mice immunized with Aβ protofibrils
39. O1–01–05: 'Arctic' mutation—a unique tau and amyloid feature in progressive dementia
40. P1–234: Diabetes, insulin resistance and risk of Alzheimer's disease
41. O3–05–07: Reduction of hyperphosphorylated–tau during memantine treatment of Alzheimer′s disease
42. O4–06–01: Docosahexaenoic acid stabilizes soluble amyloid–β protofibrils and sustains amyloid–β induced neurotoxicity In vitro
43. P2–344: PIB deposition in frontotemporal dementia in comparison with Alzheimer‘s disease and healthy volunteers: A PET study
44. P2–273: PET–imaging of amyloid depositions and astrocytosis in severe ad and histopathological correlations in one patient
45. P3–084: Differential regulation of plasma Aβ40 and Aβ42 levels with aging in the Uppsala Longitudinal Study of Adult Men (ULSAM)
46. P4–041: The Arctic Alzheimer mutation favors Aβ production by making APP less available to α–secretase at the cell surface
47. P3–092: Amyloid beta levels in plasma and CSF are correlated in healthy individuals
48. P3–150: Frontotemporal dementia and parkinsonism: A new phenotype of the tau S305S mutation
49. P1–030: Analysis of gene expression in brains of tg–APP–ArcSwe mice, a model for Alzheimer's disease
50. P1–038: Immunohistochemical and biochemical analyses of Aβ deposits in Tg–APP–ArcSwe and Tg–APP–Swe transgenic mouse brain
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.